Comprehensive genetic and histopathologic study reveals three types of neuroblastoma tumors

Journal of Clinical Oncology

Volumn 19, Issue 12, 2001, Pages 3080-3090

  Lastowska, M ^a   Cullinane, C ^a   Variend, S ^a   Cotterill, S ^a   Bown, N ^a   O'Neill, S ^a   Mazzocco, K ^a   Roberts, P ^a   Nicholson, J ^a   Ellershaw, C ^a   Pearson, A D J ^a   Jackson, M S ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CHILD; CHROMOSOME 17Q; CHROMOSOME 1P; DISEASE CLASSIFICATION; GENE AMPLIFICATION; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; MUTATION; NEUROBLASTOMA; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; TUMOR GROWTH;

EID: 0035876142     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.12.3080     Document Type: Article

References (68)

1. Successful management of low-stage neuroblastoma without adjuvant therapies: A comparison of two decades, 1972 through 1981 and 1982 through 1992, in a single institution
2. Clinical prognostic factors in 1277 patients with neuroblastoma: Results of The European Neuroblastoma Study Group Survey 1982-1992
3. Revision of the international criteria for neuroblastoma diagnosis, staging, and response to treatment
4. Minute chromatin bodies in malignant tumours of childhood
5. A novel chromosome abnormality in human neuroblastoma and antifolate-resistant Chinese hamster cell lines in culture
6. Chromosomal aberration in human neuroblastomas
7. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumor
8. Human neuroblastomas and abnormalities of chromosomes 1 and 17
9. Cellular DNA content as predictor of response to chemotherapy in infants with unresectable neuroblastoma
10. Chromosome findings and prognosis in neuroblastoma
11. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage
12. Analysis of N-myc amplification in relation to disease stage and histologic types in human neuroblastomas
13. Comparison of DNA aneuploidy, chromosome 1 abnormalities, MYCN amplification and CD44 expression as prognostic factors in neuroblastoma
14. Tumour karyotype discriminates between good and bad prognostic outcome in neuroblastoma
15. Significance of chromosome 1p loss of heterozygosity in neuroblastoma
16. Allelic loss of chromosome 1p as predictor of unfavourable outcome in patients with neuroblastoma
17. Clinical relevance of loss of heterozygosity of the short arm of chromosome 1 in neuroblastoma: A single-institution study
18. Gain of chromosome 17 is the most frequent abnormality detected in neuroblastoma by comparative genomic hybridization
19. Comparative genomic hybridization study of primary neuroblastoma tumors
20. Comparative genomic hybridization (CGH) analysis of neuroblastomas: An important methodological approach in pediatric tumor pathology
21. Genetic heterogeneity of neuroblastoma studied by comparative genomic hybridization
22. Additional copies of a 25 Mb chromosomal region originating from 17q23.1-17qter are present in 90% of high-grade neuroblastomas
23. Promiscuous translocations of chromosome arm 17q in human neuroblastomas
24. Gain of chromosome arm 17q predicts unfavorable outcome in neuroblastoma patients
25. Relative prognostic value of genetic factors in neuroblastoma
26. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma
27. Loss of heterozygosity for chromosomes 1 or 14 defines subsets of advanced neuroblastomas
28. Deletion of chromosome 11 and of 14q sequences in neuroblastoma
29. Allelotype of neuroblastoma
30. Allelic loss of the short arm of chromosome 4 in neuroblastoma suggests a novel tumor suppressor gene locus
31. Loss of heterozygosity of 3p markers in neuroblastoma tumours implicate a tumour-suppressor locus distal to the FH1T gene
32. Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas
33. Sublocalization of putative tumor suppressor gene loci on chromosome arm 14q in neuroblastoma
34. Loss of heterozygosity for the short arm of chromosome 1 in human neuroblastomas: Correlation with N-myc amplification
35. Allelic loss of chromosome 1p36 in neuroblastoma is of preferential maternal origin and correlates with N-myc amplification
36. Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: A Children's Cancer Group study
37. Gain of chromosome arm 17q is associated with unfavourable prognosis in neuroblastoma, but does not involve mutations in somatostatin receptor 2 (SSTR2) gene at 17q24
38. Molecular analysis of chromosome arm 17q gain in neuroblastoma
39. Coordinate deletion of chromosome 3p and 11q in neuroblastoma detected by comparative genomic hybridization
40. Observations on the histologic theory of neuroblastomas
41. Lymphoid infiltrates in neuroblastomas: Their occurence and prognostic significance
42. Prognostic factors in neuroblastomas
43. Prognostic value of histopathology in advanced neuroblastoma: A report from Children's Cancer Study Group
44. Histopatologic prognostic factors in neuroblastic tumors: Definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas
45. Recommendations for modification of terminology of neuroblastic tumors and prognostic significance of Shimada classification
46. Age-linked prognostic categorization based on a new histologic grading system of neuroblastomas: A clinical pathologic study of 211 cases from the Pediatric Oncology Group
47. Modified histologic grading of neuroblastoma by replacement of mitotic rate with mitosis karyorrhexis index: A clinicopathologic study of 223 cases from the Pediatric Oncology Group
48. Terminology and morphologic criteria of neuroblastic tumours
49. The International Neuroblastoma Pathology Classification (the Shimada System)
50. Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis
51. CD44: A new prognostic marker for neuroblastoma
52. Cytogenetic abnormalities of small cell tumours
53. Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors
54. Application of comparative genomic hybridization in constitutional chromosome studies
55. Nonparametric estimation from incomplete observations
56. Neuroblastoma: Effect of genetic factors on prognosis and treatment
57. Molecular biology of neuroblastoma
58. Analysis of DNA ploidy and proliferative activity in relation to histology and N-myc amplification in neuroblastoma
59. Coamplification and concomitant high levels of expression of DEAD box gene with MYCN in human neuroblastoma
60. Investigation of co-amplification of the candidate genes ornithine decarboxylase, ribonucleotide reductase, syndecan-1 and a DEAD box gene, DDXI, with N-myc in neuroblastoma
61. Clinical relevance of CD44 cell surface expression and MYCN gene amplification in neuroblastoma
62. Absence of functional CD44 hyaluronan receptor on human NMYC-amplified neuroblastoma cells
63. Role of ploidy, chromosome 1p, and Schwann cells in the maturation of neuroblastoma
64. How independent are 1p deletion and 17q gain in neuroblastoma? Significance of unbalanced translocation t(1p;17q) detected by cytogenetics and FISH
65. Two distinct deleted regions on the short arm of chromosome 1 in neuroblastoma
66. There may be two tumor suppressor genes on chromosome arm 1p closely associated with biologically distinct subtypes of neuroblastoma
67. Evidence for two tumour suppressor loci on chromosomal bands 1p-35-36 involved in neuroblastomas: One probably imprinted, another associated with N-myc amplification